产前检出先天畸形中的全基因组测序:临床环境下的前瞻性队列研究
这项前瞻性研究对50例染色体非整倍体及致病性拷贝数变异阴性、产前超声检出各种先天畸形的胎儿行三人组全基因组测序,13/50(26%)获得分子诊断,涉及FGFR3等12个基因,骨骼畸形诊断率最高(4/9,44%)。作者认为全基因组测序可增加临床相关信息,有助于判断预后、评估再发风险并提供生殖选择。
要点
- 产前超声检出畸形且非整倍体/致病性拷贝数变异阴性者,三人组全基因组测序诊断率为26%(13/50)。
- 骨骼畸形诊断率4/9(44%),多系统畸形3/7(43%),中枢神经系统畸形5/15(33%),胸部畸形1/10(10%)。
- 另有2例携带意义不明确变异但被认为可能临床相关,合计15/50(30%)检出致病或可能临床相关变异。
核心结论
- 在临床环境下对产前检出的先天畸形行全基因组测序,诊断率为26%(13/50)。
- 本研究强调全基因组测序可为胎儿结构异常的诊断带来益处。
- 作者指出,本队列在全基因组测序前已排除致病性染色体异常;未来以全基因组测序作为一线诊断试验并包含染色体异常评估的研究,可能显示检出率超过本研究的诊断率。
- 全基因组测序可增加临床相关信息,解释胎儿异常的潜在病因,提供该疾病特定预后的信息并评估再发风险。
- 遗传学诊断还可为未来妊娠提供更多生殖选择。
研究设计与样本
- 前瞻性研究,纳入50例因各种先天畸形转诊至三级中心行产前诊断的妊娠。
- 纳入标准为产前超声检出孤立或多发畸形后接受进一步检查的孕妇;排除孤立性颈项透明层增厚、配子捐赠或多胎妊娠的病例。
- 所有病例经胎儿-父母三人组全基因组测序分析,且对染色体非整倍体及致病性拷贝数变异阴性。
- 全基因组测序采用Illumina公司30×无聚合酶链反应短读长测序,分析单核苷酸变异、插入和缺失、结构变异、短串联重复序列及SMN1和SMN2基因的拷贝数。
主要发现
- 13/50(26%)病例获得分子诊断。
- 致病变异见于12个基因:FGFR3(n=2)、ACTA1(n=1)、CDH2(n=1)、COL1A2(n=1)、DHCR7(n=1)、EYA1(n=1)、FBXO11(n=1)、FRAS1(n=1)、L1CAM(n=1)、OFD1(n=1)、PDHA1(n=1)和SOX9(n=1)。
- 按表型分组的诊断率:骨骼畸形4/9(44%),多系统畸形3/7(43%),中枢神经系统畸形5/15(33%),胸部畸形1/10(10%)。
- 另有2例携带根据美国医学遗传学与基因组学学会指南评估为意义不明确的变异,但被认为可能临床相关。
- 合计检出致病或可能临床相关变异15/50(30%)。
关键数值与推荐
- 全基因组测序对产前检出先天畸形的诊断率为26%(13/50)。
- 骨骼畸形诊断率4/9(44%),多系统畸形3/7(43%),中枢神经系统畸形5/15(33%),胸部畸形1/10(10%)。
- 致病或可能临床相关变异合计检出率30%(15/50)。
- 意义不明确但可能临床相关的变异2例,依据美国医学遗传学与基因组学学会指南评估。
临床怎么用
- 作者认为全基因组测序可增加临床相关信息,解释胎儿异常的潜在病因。
- 作者认为遗传学诊断可提供该疾病特定预后的信息并评估再发风险。
- 作者认为遗传学诊断可为未来妊娠提供更多生殖选择。
局限性
- 本队列在全基因组测序前已排除致病性染色体异常,而染色体异常是产前检出先天畸形的已知原因。
- 作者指出,未来以全基因组测序作为一线诊断试验并包含染色体异常评估的研究,可能显示检出率超过本研究的诊断率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the diagnostic yield of trio whole-genome sequencing (WGS) in fetuses with various congenital malformations referred to a tertiary center for prenatal diagnosis. METHODS: In this prospective study, 50 pregnancies with different congenital malformations, negative for trisomies and causative copy-number variants, were analyzed further with fetal-parental trio WGS analysis. Parents were eligible for inclusion if they accepted further investigation following the detection of isolated or multiple malformations on prenatal ultrasound. Cases with isolated increased nuchal translucency, gamete donation or multiple pregnancy were excluded. WGS with the Illumina Inc. 30× polymerase-chain-reaction-free short-read sequencing included analysis of single-nucleotide variants, insertions and deletions, structural variants, short tandem repeats and copy-number identification of SMN1 and SMN2 genes. RESULTS: A molecular diagnosis was achieved in 13/50 (26%) cases. Causative sequence variants were identified in 12 genes: FGFR3 (n = 2), ACTA1 (n = 1), CDH2 (n = 1), COL1A2 (n = 1), DHCR7 (n = 1), EYA1 (n = 1), FBXO11 (n = 1), FRAS1 (n = 1), L1CAM (n = 1), OFD1 (n = 1), PDHA1 (n = 1) and SOX9 (n = 1). The phenotypes of the cases were divided into different groups, with the following diagnostic yields: skeletal malformation (4/9 (44%)), multisystem malformation (3/7 (43%)), central nervous system malformation (5/15 (33%)) and thoracic malformation (1/10 (10%)). Additionally, two cases carried variants that were considered potentially clinically relevant, even though they were assessed as variants of uncertain significance, according to the guidelines provided by the American College of Medical Genetics and Genomics. Overall, we identified a causative or potentially clinically relevant variant in 15/50 (30%) cases. CONCLUSIONS: We demonstrate a diagnostic yield of 26% with clinical WGS in prenatally detected congenital malformations. This study emphasizes the benefits that WGS can bring to the diagnosis of fetal structural anomalies. It is important to note that causative chromosomal aberrations were excluded from our cohort before WGS. As chromosomal aberrations are a well-known cause of prenatally detected congenital malformations, future studies using WGS as a primary diagnostic test, including assessment of chromosomal aberrations, may show that the detection rate exceeds the diagnostic yield of this study. WGS can add clinically relevant information, explaining the underlying cause of the fetal anomaly, which will provide information concerning the specific prognosis of the condition, as well as estimate the risk of recurrence. A genetic diagnosis can also provide more reproductive choice for future pregnancies. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Westenius E, Conner P, Pettersson M, et al. Whole-genome sequencing in prenatally detected congenital malformations: prospective cohort study in clinical setting. Ultrasound Obstet Gynecol. 2024. PMID: 38268232. doi:10.1002/uog.27592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。